

Lipodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/LC0C8D607C65EN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: LC0C8D607C65EN

Abstracts

The 7 major lipodystrophy markets are expected to exhibit a CAGR of 4.45% during 2024-2034.

The lipodystrophy market has been comprehensively analyzed in IMARC's new report titled "Lipodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lipodystrophy is a rare metabolic disorder characterized by abnormal fat distribution or the loss of body fat. Individuals suffering from the ailment may have excess fat in some areas, such as the neck and abdomen, and a lack of fat in other places, including the arms, legs, face, etc. The condition is often associated with metabolic complications, such as insulin resistance, diabetes, fatty liver, high levels of triglycerides in the blood, etc. Various other symptoms of lipodystrophy are muscle hypertrophy, acanthosis nigricans (dark, thickened skin), an enlarged liver or spleen, etc. The diagnosis of the ailment typically involves a combination of clinical evaluation, imaging procedures, and laboratory tests. Healthcare providers may also assess the distribution of body fat and the presence of metabolic complications, such as insulin resistance and diabetes. Numerous imaging procedures, including ultrasound and MRI, can provide information about body composition as well as fat distribution. Additionally, blood tests are also utilized to evaluate glucose and lipid levels in the patients.

The increasing cases of mutations in genes that regulate adipose tissue development and control metabolism are primarily driving the lipodystrophy market. Besides this, the widespread adoption of insulin sensitizers, such as metformin and pioglitazone, to improve glucose control as well as reduce the risk of diabetes in patients is acting as another significant growth-inducing factor. Furthermore, the escalating usage of leptin

replacement therapy in patients with generalized lipodystrophy, who have low levels of the hormone leptin, is also bolstering the market growth. This therapy helps to regulate metabolism and improves lipid levels as well as insulin sensitivity. Additionally, several key players are exploring the use of GLP-1 agonists to reduce blood sugar levels and lower the risk of cardiovascular diseases in individuals with lipodystrophy. This, in turn, is further creating a positive outlook for the market. Moreover, the ongoing development of numerous advanced imaging tests, such as DEXA scans, which provide a visual representation of body fat distribution and information regarding metabolic abnormalities that can aid in the accurate diagnosis and better management of the disorder, is expected to drive the lipodystrophy market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the lipodystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lipodystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lipodystrophy market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the lipodystrophy market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the lipodystrophy market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current lipodystrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the lipodystrophy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the lipodystrophy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the lipodystrophy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of lipodystrophy across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of lipodystrophy by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of lipodystrophy by gender across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of lipodystrophy by type across the seven major markets?

How many patients are diagnosed (?2018-2034?) with lipodystrophy across the seven major markets?

What is the size of the lipodystrophy patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of lipodystrophy?

What will be the growth rate of patients across the seven major markets?

Lipodystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for lipodystrophy drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lipodystrophy market?

What are the key regulatory events related to the lipodystrophy market?

What is the structure of clinical trial landscape by status related to the lipodystrophy market?

What is the structure of clinical trial landscape by phase related to the lipodystrophy market?

What is the structure of clinical trial landscape by route of administration related to the lipodystrophy market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 LIPODYSTROPHY - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 LIPODYSTROPHY - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 LIPODYSTROPHY - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Epidemiology by Type (?2018-2034?)
 - 7.2.6 Diagnosed Cases (?2018-2034?)
 - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Epidemiology by Type (?2018-2034?)
 - 7.3.6 Diagnosed Cases (?2018-2034?)
 - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Epidemiology by Type (?2018-2034?)
 - 7.4.6 Diagnosed Cases (?2018-2034?)
 - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Epidemiology by Type (?2018-2034?)
 - 7.5.6 Diagnosed Cases (?2018-2034?)
 - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Epidemiology by Type (?2018-2034?)
 - 7.6.6 Diagnosed Cases (?2018-2034?)

- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)
 - 7.7.4 Epidemiology by Gender (?2018-2034?)
 - 7.7.5 Epidemiology by Type (?2018-2034?)
 - 7.7.6 Diagnosed Cases (?2018-2034?)
 - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Epidemiology by Type (?2018-2034?)
 - 7.8.6 Diagnosed Cases (?2018-2034?)
 - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Epidemiology by Type (?2018-2034?)
 - 7.9.6 Diagnosed Cases (?2018-2034?)
 - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 LIPODYSTROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 LIPODYSTROPHY - UNMET NEEDS

10 LIPODYSTROPHY - KEY ENDPOINTS OF TREATMENT

11 LIPODYSTROPHY - MARKETED PRODUCTS

- 11.1 List of Lipodystrophy Marketed Drugs Across the Top 7 Markets

- 11.1.1 Myalept (Metreleptin) - Amryt Pharma
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Egrifta (Tesamorelin) - Theratechnologies
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 LIPODYSTROPHY - PIPELINE DRUGS

- 12.1 List of Lipodystrophy Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 REGN4461 - Regeneron Pharmaceuticals
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 AKCEA-ANGPTL3-LRx - Ionis Pharmaceuticals/Pfizer
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. LIPODYSTROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. LIPODYSTROPHY – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 LIPODYSTROPHY - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Lipodystrophy - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Lipodystrophy - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Lipodystrophy - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Lipodystrophy - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Lipodystrophy - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Lipodystrophy - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Lipodystrophy - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Lipodystrophy - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Lipodystrophy - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Lipodystrophy - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Lipodystrophy - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom

- 15.6.1 Lipodystrophy - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
- 15.6.2 Lipodystrophy - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Lipodystrophy - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Lipodystrophy - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Lipodystrophy - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Lipodystrophy - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Lipodystrophy - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Lipodystrophy - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Lipodystrophy - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Lipodystrophy - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Lipodystrophy - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Lipodystrophy - Access and Reimbursement Overview

16 LIPODYSTROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 LIPODYSTROPHY MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 LIPODYSTROPHY MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Lipodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/LC0C8D607C65EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LC0C8D607C65EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

